tradingkey.logo
tradingkey.logo
Search

Iovance Biotherapeutics Inc

IOVA
Add to Watchlist
3.910USD
-0.020-0.51%
Close 06/18, 16:00ETQuotes delayed by 15 min
1.75BMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
7.64
Change
0.16
The current earnings forecast score of Iovance Biotherapeutics Inc is 7.80, ranking 273 out of 389 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 17.00 and a low of 1.50.

Analyst Rating

Based on 10 analysts
Buy
Current Rating
8.800
Target Price
+118.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Iovance Biotherapeutics Inc
IOVA
10
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
112

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Iovance Biotherapeutics Inc's expected revenue for the next quarter?

Iovance Biotherapeutics Inc's expected revenue is 87.76M.

What is Iovance Biotherapeutics Inc's price target?

Analysts forecast that Iovance Biotherapeutics Inc's price target is USD 9.00, with the highest forecast at USD 17.00 and the lowest forecast at USD 1.50.

How have Iovance Biotherapeutics IncIOVA's recent earnings per share performed?

The market expectation was USD -0.19, while Iovance Biotherapeutics IncIOVA's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.13.

What is the analyst rating for Iovance Biotherapeutics Inc?

Based on the ratings of Iovance Biotherapeutics Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI